AtherosclerosisNCT03828422
Arterial Function and Atherosclerosis in Essential Thrombocythemia
An observational study of Atherosclerosis, run by University Medical Centre Ljubljana.
Trial summary
The aim of the study is to examine (a) whether patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of arterial stiffness, pulse-wave velocity and coronary calcium score in a 4 year observation period, and (b) whether the burden… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Atherosclerosis
- What is being tested?
- imaging
- How many people
- 82 participants
- Where
- No sites listed yet
- Study dates
- Jan 2014to 5 Aug 2021
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Expected patient group: 40 patients (14 male and 26 female) with JAK2 V617F positive ET without clinically apparent cardiovascular disease. Average age 55,05 (13,48); ITM 25,22 (3,65); systolic blood pressure 138 (124-150) mmHg; diastolic blood pressure 81 (74-85) mmHg; Framingham risk score for CHD 6,84%. Expected control group: 42 individuals (16 male and 26 female) who were age and sex matched with the patient group. Average age 59,16 (12,03); ITM 27,27 (4,64); systolic blood pressure 132 (125-141) mmHg; diastolic blood pressure 81 (76-86) mmHg; Framingham risk score for CHD 7,20%.
Who may be able to join
- patients with JAK2 V617F positive essential thrombocythemia
- age-and sex-matched apparently healthy control subjects
Who cannot join
- personal history of any atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)
- chronic kidney disease stage 3 and above
- known cancer
- chronic inflammatory disease
- autoimmune disease
- pregnancy
About this study
Official title: Arterial Function and Atherosclerosis in Patients With JAK2 V167F Positive Essential Thrombocythemia
The aim of the study is to examine (a) whether patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of arterial stiffness, pulse-wave velocity and coronary calcium score in a 4 year observation period, and (b) whether the burden of JAK2 V617F mutation correlates with the measured vascular parameters. All subjects will be examined twice. The first visit already took place between the years 2014 - 2015 and the second visit will take place between 2018-2019. All participants will have signed their informed consent before entering the study. Each visit will consist of completing a structured questionnaire (on personal and family medical history, risk factors for CVD and medication), physical examination, donating a blood sample for laboratory tests and undergoing carotid ultrasound and coronary calcium measurement oft the extent of coronary artery calcification. At the first and the second examination the JAK2 V617F allele burden, i.e. the percentage of mutated alleles, will be determined from genomic DNA in peripheral blood.
Read the detailed description
- Patients and control subjects Patients are selected from the database of the Department of Haematology at University Medical Centre Ljubljana, Slovenia, who were diagnosed with JAK2 V617F positive ET between 2011 and 2014. There were 124 JAK2 positive ET patients, among those 61 did not have a personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke). 40 patients (14 male and 26 female) with JAK2 V617F positive ET without clinically apparent cardiovascular disease signed the informed consent and were enrolled in the study in 2014 - 2015 for the first examination and 36 (12 male and 24 female) of them are expected to participate also in 2018-19. The control group is selected among healthy employees of the University Medical Centre Ljubljana and their relatives. It is matched with the patient group for age and sex distribution and classical risk factors for cardiovascular disease. 42 individuals (16 male and 26 female) participated in the first examination and at least 38 (14 male and 24 female) subjects are expected to paticipate in the second examination.
- Baseline measurements Each participant will complete a questionnaire about family history of cardiovascular diseases, personal medical history, smoking status and medications. A physical examination will be performed, including measurements of height, weight, waist circumference, systolic and diastolic blood pressure. Blood will be sampled for laboratory analysis of complete blood cell count, electrolytes, serum lipids, liver function tests, urea, creatinine, and inflammatory markers. The 10-year risk of coronary heart disease (CHD) and general cardiovascular disease (CVD) will be calculated using the Framingham risk equation.
- JAK2 V617F/G1849T allele burden The ipsogen JAK2 MutaQuant Kit, Qiagen (ZDA) (Ref: No. 673523) will be used for the detection and quantification of JAK2 V617F/G1849T allele in genomic DNA extracted from peripheral blood of patients and also control subjects. A SNP specific primer selectively amplifies the JAK2 V617F allele which is detected with a real-time qPCR instrument that quantifies the PCR products. The JAK2 V617F allele burden will be calculated and expressed as the percentage of JAK2 V617F mutated alleles throughout the whole JAK2 record. Analysis will be done done in laboratory of the Department of Haematology at University Medical Centre Ljubljana for all samples.
- Carotid Artery Ultrasound Examination For examination of the extracranial carotid arteries an ultrasound machine Aloka Prosound α7 (Hitachi Aloka Medical, Ltd., Japan) will be used with a linear vascular probe working at a frequency of 5-13 MHz. The common, internal and external carotid arteries on both sided will be examined. At each examination, the measurements will be done twice and their average values will be calculated. The ultrasound examination will be done by the same ultrasonographer at both visits of all participants. The intima-media thickness will be measured 2 cm proximal to the bulb of common carotid artery on both sides. Screening of the extracranial carotid arteries for atherosclerotic plaques will be performed, with a plaque definition of a focal lesion, exceeding the intima-media thickness for at least 50% or reaching an absolute thickness of at least 1.5 mm in two orthogonal projections. Scoring of atherosclerotic plaques is done according to the methodology from the Rotterdam Study. The presence of at least one plaque in each segment of the extracranial carotid arterial bed, (divided into the common carotid artery and the bulb, the internal carotid artery and the external carotid artery) on either sides is scored 1 point. Thus, the carotid plaque score ranges from 0 (absence of plaques) to 6 (plaques present in all segments on both sides). Echo-tracking of the common carotid artery will be used to assess arterial stiffness expressed by the β-stiffness index and the pulse wave velocity. Measurements will be done at the common carotid artery 2 cm proximal to the bulb on both sides. The β-stiffness index will be calculated as: β = ln (P_max / P_min) / [(D_max - D_min / D_min)], where P_max = the systolic blood pressure, P_min = the diastolic pressure; D_max = the maximum arterial diameter and D_min = the minimal arterial diameter. Pulse wave velocity (PWV) will be calculated as: PWV = √ ((β x P_min) / 2ρ)); ρ = 1050 kg/m³.
- Assessment of Endothelial Function of the Digital Arteries Endothelial function of the digital arteries will be measured by digital plethymography with EndoPat 2000, Itamar Medical REF, Caesarea, Israel, Software Version 3.3.x and expressed as the Reactive Hyperaemia Index (RHI) and the Augmentation Index (AI). Changes in arterial tone are elicited by creating a downstream hyperemic response induced by a standard 5-minute occlusion of the brachial artery (using a blood pressure cuff, inflated to 60 mmHg above the arterial blood pressure). When the cuff is released, the surge of blood flow causes endothelium-dependent flow mediated dilatation (FMD) which is manifested as reactive hyperemia. A post-occlusion to pre-occlusion ratio is calculated by EndoPAT software and the and A) are determined. The results are normalized to a heart rate of 75/min.
- Measurement of the Coronary Artery Calcium Burden The calcium burden of coronary arteries is measured with a Biograph M 128-row PET-CT scanner (Siemens, Erlangen, Germany). Scanning is done from the base to the apex of the heart. A non-contrast protocol with sequential prospective ECG triggering is used. The rotation time is 0.33 sec, with a tube voltage of 120 kV, CARE Dose 4D and slice thickness 3 mm, with no slice overlap. Post-processing is done on the Syngo Leonardo workstation. The coronary calcium burden is expressed as the Agatston score. Evaluation of the dataset of every study subject is done three times and the average value is used for further analysis.
- Statistical analysis
All sets of data will be tested for normality of distribution using the normal-quintile plot, calculating the correlation coefficient and checking it for the critical value that would warrant rejection of normal distribution with an α-error probability of 0.05.
Normally distributed data will be presented as mean and standard deviation, while non-normally distributed data will be presented as median and range between the 1st and 3rd quartile.
Differences between subjects with ET and control subjects at the first and second examination will be tested by the chi-square test for discrete variables, for normally distributed continuous variables by the paired Student's t-test for independent samples, and for non-normally distributed continuous variables by the Mann-Whitney test for independent samples. P-values of < 0.05 will be considered significant with a correction for multiple comparisons.
Changes in vascular function and morphology in the 4-year observation period will be compared between the two groups by the log rank test. P-values of < 0.05 will be considered significant.
The association between the parameters of vascular function / morphology and the JAK2 V617F allele burden will be assessed by the Pearson correlation coefficient.
- Conditions
- Atherosclerosis
- Being tested
- imaging
- Keywords
- essential thrombocythaemia, JAK2 V617F mutation burden, preclinical atherosclerosis, arterial stiffness, endothelial function, coronary artery calcium score
- Medical subject headings
- Atherosclerosis, Thrombocythemia, Essential
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
imagingDiagnostic test
Also called EndoPat plethysmography, coronary artery calcium scanning, blood laboratory tests, ultrasound examination
| Study group | Role | What they receive |
|---|---|---|
| patients with essential thrombocythemia | * essential thrombocythemia with JAK2 V617F positive mutation
* patients from the Department of Haematology at University Medical Centre Ljubljana, Slovenia, who were diagnosed with JAK2 V617F positive ET between 2011 and 2014
* no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)
* all signed the informed consent
* examined twice, the first time in the years 2014-2015 and for the second time in the years 2018-2019
* blood for laboratory tests
* imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning Receives: Diagnostic Test: imaging | |
| control group | * the control group is selected among healthy employees of the University Medical Centre Ljubljana and their relatives
* they are matched with the patient group for age and sex distribution and classical risk factors for cardiovascular disease
* no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)
* all signed the informed consent
* blood for laboratory tests
* examined twice, the first time in the years 2014-2015 and for the second time the in years 2018-2019
* imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning Receives: Diagnostic Test: imaging |
What is being measured
The primary outcome is the main question the study is designed to answer.
Carotid Artery Stiffness (Expressed by Beta-stiffness Index ) in JAK2 V617F Positive ET Patients in Comparison to Healthy Control Subjects in a 4-year Period (From Baseline to Year 4).
4-year change carotid artery in Beta-stiffness Index measured in JAK2 V617F positive ET patients in comparison to healthy control subjects. All measurements were performed by echo-tracking ultrasound of the common carotid artery.
Echo-tracking of the common carotid artery wall was used to assess arterial stiffness expressed by the β-stiffness index. Measurement swere done at the common carotid artery 2 cm proximal to the bulb on both sides. The β-stiffness index was calculated as: β = ln (P_max / P_min) / [(D_max - D_min / D_min)] (P_max = the systolic blood pressure, P_min = the diastolic pressure; D_max = the maximum arterial diameter and D_min = the minimal arterial diameter). In the adult population, the values of β range from 4 - 10 and increase with age. A larger value of β means increased arterial stiffness, i.e., a worse outcome.
Measured: From Baseline (in 2014-2015) to Year 4 (in 2018-2019)
Carotid Artery Stiffness (Expressed by the Pulse Wave Velocity) in JAK2 V617F Positive ET Patients in Comparison to Healthy Control Subjects in a 4-year Period (From Baseline to Year 4).
4-year change in carotid artery pulse wave velocity (PWV) measured in JAK2 V617F positive ET patients in comparison to healthy control subjects. All measurements were performed by echo-tracking ultrasound of the common carotid artery.
Measurements were done at the common carotid artery 2 cm proximal to the bulb on both sides. PWV was calculated from the beta stiffness index (β, for description see above), as follows:
PWV = √ ((β x P_min) / 2ρ)); ρ = 1050 kg/m³. PWV increases with arterial stiffness, a larger value means a worse outcome. PWV in adults ranges from 3 m/s to 12 m/s; values are strongly age dependent.
Measured: From Baseline (in 2014-2015) to Year 4 (in 2018-2019)
Change of Carotid Artery Plaque Score in JAK2 V617F Positive ET Patients in Comparison to Healthy Control Subjects in a 4-year Period.
Change in carotid plaque score (i.e., the number of carotid artery segments with detected plaques, reported on a scale from 0-6) in a 4 year observation period.
A carotid plaque score 0 means that the common carotid, internal carotid and exteranal carotid artery on both sides are free from plaques. A score of 6 means that the common carotid, internal carotid and external carotid artery on both sides have plaques detected by ultrasound.
Measured: From Baseline (in 2014-2015) to Year 4 (in 2018-2019)
Change of Coronary Calcium Burden in JAK2 V617F Positive ET Patients in Comparison to Healthy Control Subjects in a 4-year Period.
Change in the Agatston coronary artery calcium score in a 4 year observation period.
Agatston score denotes the number of coronary artery calcifications weighted for the intensity of calcification.
Grading of coronary artery disease (CAD) based od Agatston score goes as follows: no CAD = score 0, minimal CAD = score 1-10, mild CAD = score 11-100, moderate CAD = score 101-400, svere CAD = score > 400.
Measured: From Baseline (in 2014-2015) to Year 4 (in 2018-2019)
Change of Digital Endothelial Function, Expressed as Reactive Hyperemia Index and Augmentation Index (AI), in JAK2 V617F Positive ET Patients in Comparison to Healthy Control Subjects in a 4-year Period.
4-year change in Reactive Hyperemia Index (RHI) and 4-year change Augmentation Index (AI).
RHI was calculated by the formula:
RHI = (A/B) / (C/D) where A is the post-occlusion pulse wave amplitude (PWA) of the occluded hand, B the baseline PWA of the occluded hand, C the post-occlusion PWA of the contralateral hand, and D the baseline PWA of the contralateral hand. A higher RHI means better endothelial function (= good outcome). RHI in patients ranges from1-3. Arbitrarily, normal RHI is defined as => 1.67, and abnormal RHI as RHI =< 1.66.
The AI was determined from the shape of the arterial pulse wave by the EndoPAT 2000 software which distinguished between the primary pulse wave (P1) and the reflected pulse wave (P2) by the formula: AI = ((P2-P1)/P1) x 100. The results were normalized to a heart rate of 75/min. A higher AI means greater arterial stiffness (= bad outcome). AI >0.4 is abnormal.
Measured: From Baseline (in 2014-2015) to Year 4 (in 2018-2019)
The JAK2 V617F Mutation Burden in Patients With JAK2 V617F Positive ET.
Change in JAK2 V617F mutation burden in the 4-year observation period. Ipsogen JAK2 MutaQuant Kit, Qiagen (USA) was used for the detection of JAK2 V617F mutation and quantification of its burden in genomic DNA, which was extracted from granulocytes in peripheral blood. Real-time quantitative polymerase chain reaction (qPCR) was used with double-dye oligonucleotide hydrolysis principle. The JAK2 V617F burden was defined as the percentage of JAK2 V617F mutated alleles in total genomic DNA.
Measured: At baseline (in 2014- 2015) and at the second visit (in 2018-2019)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2019
- Study startJan 2014
- Primary completionAug 2021
- Study completion5 Aug 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for AtherosclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 82 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Medical Centre Ljubljana
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ales Blinc, University Medical Centre Ljubljana
- Investigators
- Ales Blinc, MD, Study director, University Medical Centre Ljubljana
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03828422
- Sponsor's protocol ID
- TP20180038
- Status last verified
- Oct 2021
- First submitted
- 23 Jan 2019
- Last updated
- 4 Nov 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Vrtovec M, Anzic A, Zupan IP, Zaletel K, Blinc A. Carotid Artery Stiffness, Digital Endothelial Function, and Coronary Calcium in Patients with Essential Thrombocytosis, Free of Overt Atherosclerotic Disease. Radiol Oncol. 2017 Jan 14;51(2):203-210. doi: 10.1515/raon-2017-0006. eCollection 2017 Jun.
PubMed 28740456Anzic Drofenik A, Vrtovec M, Bozic Mijovski M, Sever M, Preloznik Zupan I, Kejzar N, Blinc A. Progression of coronary calcium burden and carotid stiffness in patients with essential thrombocythemia associated with JAK2 V617F mutation. Atherosclerosis. 2020 Mar;296:25-31. doi: 10.1016/j.atherosclerosis.2020.01.001. Epub 2020 Jan 11.
PubMed 32005002
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Arterial Function and Atherosclerosis in Patients With JAK2 V167F Positive Essential Thrombocythemia
- ClinicalTrials.gov ID
- NCT03828422
- Acronym / sponsor ID
- TP20180038
- Conditions
- Atherosclerosis
- Keywords
- essential thrombocythaemia, JAK2 V617F mutation burden, preclinical atherosclerosis, arterial stiffness, endothelial function, coronary artery calcium score
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 82 participants (actual)
- Lead sponsor
- University Medical Centre LjubljanaUniversity, hospital or other
- Study start
- Jan 2014 (actual)
- Primary completion
- Aug 2021 (actual)
- Study completion
- 5 Aug 2021 (actual)
- First posted
- 4 Feb 2019 (actual)
- Results
- Posted 4 Nov 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to examine (a) whether patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of arterial stiffness, pulse-wave velocity and coronary calcium score in a 4 year observation period, and (b) whether the burden of JAK2 V617F mutation correlates with the measured vascular parameters. All subjects will be examined twice. The first visit already took place between the years 2014 - 2015 and the second visit will take place between 2018-2019. All participants will have signed their informed consent before entering the study. Each visit will consist of completing a structured questionnaire (on personal and family medical history, risk factors for CVD and medication), physical examination, donating a blood sample for laboratory tests and undergoing carotid ultrasound and coronary calcium measurement oft the extent of coronary artery calcification. At the first and the second examination the JAK2 V617F allele burden, i.e. the percentage of mutated alleles, will be determined from genomic DNA in peripheral blood.
Detailed description
- Patients and control subjects Patients are selected from the database of the Department of Haematology at University Medical Centre Ljubljana, Slovenia, who were diagnosed with JAK2 V617F positive ET between 2011 and 2014. There were 124 JAK2 positive ET patients, among those 61 did not have a personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke). 40 patients (14 male and 26 female) with JAK2 V617F positive ET without clinically apparent cardiovascular disease signed the informed consent and were enrolled in the study in 2014 - 2015 for the first examination and 36 (12 male and 24 female) of them are expected to participate also in 2018-19. The control group is selected among healthy employees of the University Medical Centre Ljubljana and their relatives. It is matched with the patient group for age and sex distribution and classical risk factors for cardiovascular disease. 42 individuals (16 male and 26 female) participated in the first examination and at least 38 (14 male and 24 female) subjects are expected to paticipate in the second examination.
- Baseline measurements Each participant will complete a questionnaire about family history of cardiovascular diseases, personal medical history, smoking status and medications. A physical examination will be performed, including measurements of height, weight, waist circumference, systolic and diastolic blood pressure. Blood will be sampled for laboratory analysis of complete blood cell count, electrolytes, serum lipids, liver function tests, urea, creatinine, and inflammatory markers. The 10-year risk of coronary heart disease (CHD) and general cardiovascular disease (CVD) will be calculated using the Framingham risk equation.
- JAK2 V617F/G1849T allele burden The ipsogen JAK2 MutaQuant Kit, Qiagen (ZDA) (Ref: No. 673523) will be used for the detection and quantification of JAK2 V617F/G1849T allele in genomic DNA extracted from peripheral blood of patients and also control subjects. A SNP specific primer selectively amplifies the JAK2 V617F allele which is detected with a real-time qPCR instrument that quantifies the PCR products. The JAK2 V617F allele burden will be calculated and expressed as the percentage of JAK2 V617F mutated alleles throughout the whole JAK2 record. Analysis will be done done in laboratory of the Department of Haematology at University Medical Centre Ljubljana for all samples.
- Carotid Artery Ultrasound Examination For examination of the extracranial carotid arteries an ultrasound machine Aloka Prosound α7 (Hitachi Aloka Medical, Ltd., Japan) will be used with a linear vascular probe working at a frequency of 5-13 MHz. The common, internal and external carotid arteries on both sided will be examined. At each examination, the measurements will be done twice and their average values will be calculated. The ultrasound examination will be done by the same ultrasonographer at both visits of all participants. The intima-media thickness will be measured 2 cm proximal to the bulb of common carotid artery on both sides. Screening of the extracranial carotid arteries for atherosclerotic plaques will be performed, with a plaque definition of a focal lesion, exceeding the intima-media thickness for at least 50% or reaching an absolute thickness of at least 1.5 mm in two orthogonal projections. Scoring of atherosclerotic plaques is done according to the methodology from the Rotterdam Study. The presence of at least one plaque in each segment of the extracranial carotid arterial bed, (divided into the common carotid artery and the bulb, the internal carotid artery and the external carotid artery) on either sides is scored 1 point. Thus, the carotid plaque score ranges from 0 (absence of plaques) to 6 (plaques present in all segments on both sides). Echo-tracking of the common carotid artery will be used to assess arterial stiffness expressed by the β-stiffness index and the pulse wave velocity. Measurements will be done at the common carotid artery 2 cm proximal to the bulb on both sides. The β-stiffness index will be calculated as: β = ln (P_max / P_min) / [(D_max - D_min / D_min)], where P_max = the systolic blood pressure, P_min = the diastolic pressure; D_max = the maximum arterial diameter and D_min = the minimal arterial diameter. Pulse wave velocity (PWV) will be calculated as: PWV = √ ((β x P_min) / 2ρ)); ρ = 1050 kg/m³.
- Assessment of Endothelial Function of the Digital Arteries Endothelial function of the digital arteries will be measured by digital plethymography with EndoPat 2000, Itamar Medical REF, Caesarea, Israel, Software Version 3.3.x and expressed as the Reactive Hyperaemia Index (RHI) and the Augmentation Index (AI). Changes in arterial tone are elicited by creating a downstream hyperemic response induced by a standard 5-minute occlusion of the brachial artery (using a blood pressure cuff, inflated to 60 mmHg above the arterial blood pressure). When the cuff is released, the surge of blood flow causes endothelium-dependent flow mediated dilatation (FMD) which is manifested as reactive hyperemia. A post-occlusion to pre-occlusion ratio is calculated by EndoPAT software and the and A) are determined. The results are normalized to a heart rate of 75/min.
- Measurement of the Coronary Artery Calcium Burden The calcium burden of coronary arteries is measured with a Biograph M 128-row PET-CT scanner (Siemens, Erlangen, Germany). Scanning is done from the base to the apex of the heart. A non-contrast protocol with sequential prospective ECG triggering is used. The rotation time is 0.33 sec, with a tube voltage of 120 kV, CARE Dose 4D and slice thickness 3 mm, with no slice overlap. Post-processing is done on the Syngo Leonardo workstation. The coronary calcium burden is expressed as the Agatston score. Evaluation of the dataset of every study subject is done three times and the average value is used for further analysis.
- Statistical analysis
All sets of data will be tested for normality of distribution using the normal-quintile plot, calculating the correlation coefficient and checking it for the critical value that would warrant rejection of normal distribution with an α-error probability of 0.05.
Normally distributed data will be presented as mean and standard deviation, while non-normally distributed data will be presented as median and range between the 1st and 3rd quartile.
Differences between subjects with ET and control subjects at the first and second examination will be tested by the chi-square test for discrete variables, for normally distributed continuous variables by the paired Student's t-test for independent samples, and for non-normally distributed continuous variables by the Mann-Whitney test for independent samples. P-values of < 0.05 will be considered significant with a correction for multiple comparisons.
Changes in vascular function and morphology in the 4-year observation period will be compared between the two groups by the log rank test. P-values of < 0.05 will be considered significant.
The association between the parameters of vascular function / morphology and the JAK2 V617F allele burden will be assessed by the Pearson correlation coefficient.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| patients with essential thrombocythemia | – | Diagnostic Test: imaging* essential thrombocythemia with JAK2 V617F positive mutation * patients from the Department of Haematology at University Medical Centre Ljubljana, Slovenia, who were diagnosed with JAK2 V617F positive ET between 2011 and 2014 * no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke) * all signed the informed consent * examined twice, the first time in the years 2014-2015 and for the second time in the years 2018-2019 * blood for laboratory tests * imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning |
| control group | – | Diagnostic Test: imaging* the control group is selected among healthy employees of the University Medical Centre Ljubljana and their relatives * they are matched with the patient group for age and sex distribution and classical risk factors for cardiovascular disease * no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke) * all signed the informed consent * blood for laboratory tests * examined twice, the first time in the years 2014-2015 and for the second time the in years 2018-2019 * imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Expected patient group: 40 patients (14 male and 26 female) with JAK2 V617F positive ET without clinically apparent cardiovascular disease. Average age 55,05 (13,48); ITM 25,22 (3,65); systolic blood pressure 138 (124-150) mmHg; diastolic blood pressure 81 (74-85) mmHg; Framingham risk score for CHD 6,84%. Expected control group: 42 individuals (16 male and 26 female) who were age and sex matched with the patient group. Average age 59,16 (12,03); ITM 27,27 (4,64); systolic blood pressure 132 (125-141) mmHg; diastolic blood pressure 81 (76-86) mmHg; Framingham risk score for CHD 7,20%.
Key inclusion criteria (2 listed)
- patients with JAK2 V617F positive essential thrombocythemia
- age-and sex-matched apparently healthy control subjects
Key exclusion criteria (6 listed)
- personal history of any atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)
- chronic kidney disease stage 3 and above
- known cancer
- chronic inflammatory disease
- autoimmune disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| imagingAlso: EndoPat plethysmography, coronary artery calcium scanning, blood laboratory tests, ultrasound examination | Diagnostic test | control group, patients with essential thrombocythemia |
Primary outcome
Carotid Artery Stiffness (Expressed by Beta-stiffness Index ) in JAK2 V617F Positive ET Patients in Comparison to Healthy Control Subjects in a 4-year Period (From Baseline to Year 4).
Time frame: From Baseline (in 2014-2015) to Year 4 (in 2018-2019)
4-year change carotid artery in Beta-stiffness Index measured in JAK2 V617F positive ET patients in comparison to healthy control subjects. All measurements were performed by echo-tracking ultrasound of the common carotid artery. Echo-tracking of the common carotid artery wall was used to assess arterial stiffness expressed by the β-stiffness index. Measurement swere done at the common carotid artery 2 cm proximal to the bulb on both sides. The β-stiffness index was calculated as: β = ln (P_max / P_min) / [(D_max - D_min / D_min)] (P_max = the systolic blood pressure, P_min = the diastolic pressure; D_max = the maximum arterial diameter and D_min = the minimal arterial diameter). In the adult population, the values of β range from 4 - 10 and increase with age. A larger value of β means increased arterial stiffness, i.e., a worse outcome.
Carotid Artery Stiffness (Expressed by the Pulse Wave Velocity) in JAK2 V617F Positive ET Patients in Comparison to Healthy Control Subjects in a 4-year Period (From Baseline to Year 4).
Time frame: From Baseline (in 2014-2015) to Year 4 (in 2018-2019)
4-year change in carotid artery pulse wave velocity (PWV) measured in JAK2 V617F positive ET patients in comparison to healthy control subjects. All measurements were performed by echo-tracking ultrasound of the common carotid artery. Measurements were done at the common carotid artery 2 cm proximal to the bulb on both sides. PWV was calculated from the beta stiffness index (β, for description see above), as follows: PWV = √ ((β x P_min) / 2ρ)); ρ = 1050 kg/m³. PWV increases with arterial stiffness, a larger value means a worse outcome. PWV in adults ranges from 3 m/s to 12 m/s; values are strongly age dependent.
Change of Carotid Artery Plaque Score in JAK2 V617F Positive ET Patients in Comparison to Healthy Control Subjects in a 4-year Period.
Time frame: From Baseline (in 2014-2015) to Year 4 (in 2018-2019)
Change in carotid plaque score (i.e., the number of carotid artery segments with detected plaques, reported on a scale from 0-6) in a 4 year observation period. A carotid plaque score 0 means that the common carotid, internal carotid and exteranal carotid artery on both sides are free from plaques. A score of 6 means that the common carotid, internal carotid and external carotid artery on both sides have plaques detected by ultrasound.
Change of Coronary Calcium Burden in JAK2 V617F Positive ET Patients in Comparison to Healthy Control Subjects in a 4-year Period.
Time frame: From Baseline (in 2014-2015) to Year 4 (in 2018-2019)
Change in the Agatston coronary artery calcium score in a 4 year observation period. Agatston score denotes the number of coronary artery calcifications weighted for the intensity of calcification. Grading of coronary artery disease (CAD) based od Agatston score goes as follows: no CAD = score 0, minimal CAD = score 1-10, mild CAD = score 11-100, moderate CAD = score 101-400, svere CAD = score > 400.
Change of Digital Endothelial Function, Expressed as Reactive Hyperemia Index and Augmentation Index (AI), in JAK2 V617F Positive ET Patients in Comparison to Healthy Control Subjects in a 4-year Period.
Time frame: From Baseline (in 2014-2015) to Year 4 (in 2018-2019)
4-year change in Reactive Hyperemia Index (RHI) and 4-year change Augmentation Index (AI). RHI was calculated by the formula: RHI = (A/B) / (C/D) where A is the post-occlusion pulse wave amplitude (PWA) of the occluded hand, B the baseline PWA of the occluded hand, C the post-occlusion PWA of the contralateral hand, and D the baseline PWA of the contralateral hand. A higher RHI means better endothelial function (= good outcome). RHI in patients ranges from1-3. Arbitrarily, normal RHI is defined as => 1.67, and abnormal RHI as RHI =< 1.66. The AI was determined from the shape of the arterial pulse wave by the EndoPAT 2000 software which distinguished between the primary pulse wave (P1) and the reflected pulse wave (P2) by the formula: AI = ((P2-P1)/P1) x 100. The results were normalized to a heart rate of 75/min. A higher AI means greater arterial stiffness (= bad outcome). AI >0.4 is abnormal.
The JAK2 V617F Mutation Burden in Patients With JAK2 V617F Positive ET.
Time frame: At baseline (in 2014- 2015) and at the second visit (in 2018-2019)
Change in JAK2 V617F mutation burden in the 4-year observation period. Ipsogen JAK2 MutaQuant Kit, Qiagen (USA) was used for the detection of JAK2 V617F mutation and quantification of its burden in genomic DNA, which was extracted from granulocytes in peripheral blood. Real-time quantitative polymerase chain reaction (qPCR) was used with double-dye oligonucleotide hydrolysis principle. The JAK2 V617F burden was defined as the percentage of JAK2 V617F mutated alleles in total genomic DNA.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 28740456Vrtovec M, Anzic A, Zupan IP, Zaletel K, Blinc A. Carotid Artery Stiffness, Digital Endothelial Function, and Coronary Calcium in Patients with Essential Thrombocytosis, Free of Overt Atherosclerotic Disease. Radiol Oncol. 2017 Jan 14;51(2):203-210. doi: 10.1515/raon-2017-0006. eCollection 2017 Jun.
- Results publication: PubMed 32005002Anzic Drofenik A, Vrtovec M, Bozic Mijovski M, Sever M, Preloznik Zupan I, Kejzar N, Blinc A. Progression of coronary calcium burden and carotid stiffness in patients with essential thrombocythemia associated with JAK2 V617F mutation. Atherosclerosis. 2020 Mar;296:25-31. doi: 10.1016/j.atherosclerosis.2020.01.001. Epub 2020 Jan 11.
- Individual participant dataSharing planned: Undecided
Related trials for Atherosclerosis
RecruitingObservational study
Study of the Effect of Innate on the Inflammatory Response to Endotoxin
Asthma, Atherosclerosis
Not yet recruitingObservational study
Qatar Cardiometabolic Cohort
Cardiometabolic Diseases
RecruitingObservational study
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
Metabolic Disease, Obesity
RecruitingObservational study
Causes and Natural History of Dyslipidemias
Hypercholesterolemia, Atherosclerosis
Active, not recruitingPhase 4
Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization
Coronary Artery Disease, Atherosclerosis of Coronary Artery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ales Blinc, MD study director
University Medical Centre Ljubljana
Questions about this trial
What is this clinical trial studying?
An observational study of Atherosclerosis, run by University Medical Centre Ljubljana.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 4 Nov 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Carotid Artery Stiffness (Expressed by Beta-stiffness Index ) in JAK2 V617F Positive ET Patients in Comparison to Healthy Control Subjects in a 4-year Period (From Baseline to Year 4). (time frame: From Baseline (in 2014-2015) to Year 4 (in 2018-2019)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03828422, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2021.